Lakefront Biotherapeutics/€LKFT
Lakefront Biotherapeutics shares rise after its nine-month results showed a return to profit, aided by financial income, and the company announced a further €50 million share buyback.
10 hours agoLightyear AI
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Lakefront Biotherapeutics
Galapagos NV, abbreviated as GLPG on stock exchanges, is a global biotechnology firm specializing in the discovery and development of small molecule medicines. The company focuses on innovating treatments primarily in the fields of immunology and oncology. Founded in 1999, Galapagos operates out of its headquarters in Belgium and extends its reach across Europe and the United States, aiming to provide transformative therapies for significant unmet medical needs.
- Ticker
- €LKFT
- Sector
- Health
- Primary listing
- AEX
- Employees
- 196
- Headquarters
- Mechelen, Belgium
- Website
- lakefrontbio.com
LKFT Metrics
BasicAdvanced
€1.9B
3.32
€9.02
0.12
-
Price and volume
Market cap
€1.9B
Beta
0.12
52-week high
€30.50
52-week low
€22.70
Average daily volume
82K
Financial strength
Current ratio
32.839
Quick ratio
32.647
Long term debt to equity
0.001
Total debt to equity
0.002
Interest coverage (TTM)
664.53%
Profitability
EBITDA (TTM)
568.918
Gross margin (TTM)
67.61%
Net profit margin (TTM)
60.23%
Operating margin (TTM)
64.99%
Effective tax rate (TTM)
-2.90%
Revenue per employee (TTM)
€5,050,000
Management effectiveness
Return on assets (TTM)
9.93%
Return on equity (TTM)
20.12%
Valuation
Price to earnings (TTM)
3.323
Price to revenue (TTM)
2.002
Price to book
0.6
Price to tangible book (TTM)
0.6
Price to free cash flow (TTM)
-8.533
Free cash flow yield (TTM)
-11.72%
Free cash flow per share (TTM)
-3.514
Growth
Revenue change (TTM)
259.41%
Earnings per share change (TTM)
-308.93%
3-year revenue growth (CAGR)
125.91%
10-year revenue growth (CAGR)
29.90%
3-year earnings per share growth (CAGR)
55.78%
10-year earnings per share growth (CAGR)
22.05%
What the Analysts think about LKFT
Analyst ratings (Buy, Hold, Sell) for Lakefront Biotherapeutics stock.
Analyst projections of the future price of Lakefront Biotherapeutics stock.
Bulls say / Bears say
Early Phase 1b findings for gamgertamig suggest some patients may retain remission after B-cell recovery without background treatment. The company plans to expand trials and expects registrational studies to begin in 2027, giving its lead programme a route towards larger studies. (Lakefront Biotherapeutics)
Gilead’s acquisition of Ouro gives Lakefront a major development partner for gamgertamig: Gilead will lead later-stage trials, while Lakefront is eligible for 20–23% royalties on sales outside Keymed’s territories. That could let Lakefront share in commercial upside without carrying the full cost of global development and sales. (Lakefront Biotherapeutics)
Lakefront expects to end 2026 with €2.0–€2.05 billion in cash and investments, even after a second €50 million share buyback. It says at least €1.6 billion would remain after funding the portfolio through a potential first gamgertamig approval, leaving substantial scope for further deals or other capital returns. (Lakefront Biotherapeutics)
The development portfolio is narrowing: Lakefront is winding down its cell-therapy work and has discontinued GLPG3667. This leaves investors with fewer programmes to offset a setback in the remaining pipeline. (Lakefront Biotherapeutics)
Gamgertamig remains investigational, and the encouraging remission observations are early Phase 1b findings rather than proof of lasting benefit in larger trials. Registrational studies are not expected to start until 2027, so clinical and timing risks remain substantial. (Lakefront Biotherapeutics)
Nine-month revenue was €26.1 million and Lakefront recorded a €148.4 million operating loss. The comparison with 2025 is distorted by a one-off platform revenue release, but the current figures still show a limited revenue base against ongoing costs. (Lakefront Biotherapeutics)
Data summarised monthly by Lightyear AI. Last updated on 12 Nov 2026.
LKFT Financial Performance
Revenues and expenses
LKFT Earnings Performance
Company profitability
Upcoming events
No upcoming events
Funds containing LKFT
AllUSDEURGBP
Fund name | Fund size | €LKFT weighting |
|---|---|---|
iShares Healthcare Innovation£DRDR | $1.6B | 0.11% |
iShares Healthcare Innovation$HEAL | $1.6B | 0.11% |
iShares Healthcare Innovation€2B78 | $1.6B | 0.11% |
Xtrackers MSCI Europe Small Cap£XXSC | $3.7B | 0.06% |
Xtrackers MSCI Europe Small Cap€DX2J | $3.7B | 0.06% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.